1YANG W, LUJ, WENGJ, et al. Prevalence of diabetes among men and women in China[J]. N EnglJ Med , 2010, 362(2): 1090-1101.
2SCHRODER K, TSCHOPPJ. The inflammasomes. Cell, 2010, 140(6): 821-832.
3LAMKANFI M, WALLE LV, KANNEGANTI T D. Deregulated inflammasome signaling in disease[J]. Immunol Rev, 2011, 243(1): 163-173.
4DE NARDO D, LATZ E. NLRP3 inflammasomes link inflammation and metabolic disease[J]. Trends Immunol, 2011,32(8): 373-379.
5BRYANT C, FITZGERALD K A. Molecular mechanisms involved in inflammasome activation[J]. Trends Cell Biol , 2009, 19(9): 455-464.
6ZHOU R, YAZDI A S, MENU r. et al. A role for mitochondria in NLRP3 inflammasome activation[J]. Nature, 2011, 469(7329): 221-225.
7MARTINON F. Signaling by ROS drives inflammasome activation[J]. EurJ Irnmunol , 2010, 40(3): 616-619.
8SCHRODER K, ZHOU R, TSCHOPPJ. The NLRP3 inflammasome , a sensor for metabolic danger[J]. Science, 2010, 327(5963): 296-300.
9MAEDLER K, DHARMADHIKARI G, SCHUMANN D M, et al, Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes[J]. Handb Exp Pharrnacol , 2011, (203): 257-278.
10KOENEN T B, STIENSTRA R, VAN TITS LJ. et al. The inflammasome and caspase-I activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue[J]. Endocrinology, 2011, 152(10): 3769-3778.
